Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
نویسندگان
چکیده
Extended 5-Year Follow-up of the PFO Closure Trial In initial report Gore REDUCE trial patent foramen ovale closure, with a median follow-up 3.2 years, 18 patients had stroke recur...
منابع مشابه
Recurrent Stroke after Transcatheter PFO Closure in Cryptogenic Stroke or Tia: Long-Term Follow-Up
Background There are few data on the mechanism of recurrent neurological events after transcatheter closure of patent foramen ovale (PFO) in cryptogenic stroke or TIA. Methods We retrospectively reviewed PFO closure procedures for the secondary prevention of cryptogenic stroke/TIA performed between 1999 and 2014 in Bologna, Italy. Results Written questionnaires were completed by 402 patient...
متن کاملPFO and cryptogenic stroke: Do we finally have closure?
In up to 40 percent of patients with acute ischemic stroke, the etiology remains uncertain [1]. The association of a PFO with stroke in a young woman with cerebral arterial embolism was first described in 1877 [2]. Lechat et al. later described the high prevalence of PFO in adults younger than 55 years of age when no identifiable cause of stroke could be identified [3]. They suggested that para...
متن کاملCritique of closure or medical therapy for cryptogenic stroke with patent foramen ovale: the hole truth?
It is widely accepted that venous thromboemboli can gain access to the left atrium through a patent foramen ovale (PFO). In stroke patients, this mechanism is generally presumed when no other source of stroke is found and a PFO is discovered. Rarely is a thrombus caught straddling the interatrial septum across a PFO. It is intuitively obvious that if the PFO is closed, then a patient cannot exp...
متن کاملClosure or medical therapy for cryptogenic stroke with patent foramen ovale.
BACKGROUND The prevalence of patent foramen ovale among patients with cryptogenic stroke is higher than that in the general population. Closure with a percutaneous device is often recommended in such patients, but it is not known whether this intervention reduces the risk of recurrent stroke. METHODS We conducted a multicenter, randomized, open-label trial of closure with a percutaneous devic...
متن کاملPFO Closure: CLOSURE.
T he optimal secondary prevention strategy in patients presenting with a cryptogenic stroke or transient ischemic attack (TIA) and a patent foramen ovale (PFO) is uncertain. In the United States, closure of a PFO using a percutaneous transcatheter device is currently considered investigational by the Food and Drug Administration. Nonetheless, many patients in this setting are treated off-label ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The New England Journal of Medicine
سال: 2021
ISSN: ['0028-4793', '1533-4406']
DOI: https://doi.org/10.1056/nejmc2033779